Serial liquid biopsies - the NETest - in gastroenteropancreatic NET surveillance

#3402

Introduction: Current general biomarkers are insufficient to predict the disease course in individual patients with gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs).

Aim(s): To evaluate if serial NETest measurements – a blood-based gene expression signature – reflect disease evolution over time and can predict treatment response.

Materials and methods: A median of 4 NETest samples were collected in 132 GEP-NET patients over 46 (6-71) months of follow-up. NETest scores were compared with RECIST1.1 defined disease status in patients with a watch-and-wait strategy and with treatment response in patients undergoing systemic treatment.

Conference:

Presenting Author:

Authors: van Treijen M, Korse C, Verbeek W, Tesselaar M, Valk G,

Keywords: GEP-NET, disease status, prediction, treatment response, surveillance,